Myocardial Infarction News and Research

RSS

Abiomed announces new data from its USpella IRB registry of Impella 2.5 patients

Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).

23 Sep 2009

Smoking bans result in consistent decline in heart attack rates: Study

A consistent decline in heart attack rates following the implementation of smoking bansStrongly enforced legislation to restrict smoking produces rapid and substantial reductions in community rates of heart attack, according to a meta-analysis published today in Circulation, the journal of the American Heart Association.

22 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009

Three-year clinical results of Medtronic's Resolute Zotarolimus-Eluting Coronary Stent released

New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up.

22 Sep 2009

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

St. Jude Medical, Inc. (NYSE: STJ) today announced the first use of the PressureWire™ Aeris technology, an interventional tool which measures Fractional Flow Reserve (FFR) to evaluate the severity of blood flow blockages in the arteries. This first-to-market technology helps interventional cardiologists better determine the ideal treatment option for their patients during coronary interventions, such as stent procedures.

22 Sep 2009

Heart Institute's first LHIN program in Ontario for emergency heart attacks

Heart attack victims who live outside Ottawa's urban centre now are part of the University of Ottawa Heart Institute's (UOHI) far-reaching emergency life-saving program, ensuring urgent standardized treatment regardless of geography and, for the first time in Ontario, throughout an entire regional health district.

18 Sep 2009

Study: Therapy addition reduces risk of stroke and other cardiovascular events

Data from the independent KYOTO HEART study, presented recently at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published online in the European Heart Journal demonstrated the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events(1) including stroke, compared to conventional non-ARB treatment regimen.(1)

17 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

New critical illness plan from Colonial Life introduced

A new critical illness plan from Colonial Life & Accident Insurance Company can help many working Americans who may be one serious medical issue away from financial problems. Even with good health insurance, a serious illness, such as a heart attack or stroke, could leave employees on the hook for huge expenses.

15 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

First patient enrolled in Phase 2b RADAR clinical trial

Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.

11 Sep 2009

Study reveals elevated cTnT levels in post-CABG patients

Levels of a biomarker used in the diagnosis of heart attacks are almost universally elevated in patients who have undergone coronary-artery bypass grafting (CABG) and, when markedly elevated, are powerfully prognostic, a team of researchers from the Massachusetts General Hospital (MGH) Heart Center has found.

5 Sep 2009

Boston Scientific reports two-year data from SYNTAX clinical trial

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

SYNTAX clinical trial results announced

Boston Scientific Corporation (NYSE: BSX) today announced two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the TAXUS((R)) Express((R)) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

ICD implantation reduces mortality in heart attack patients

Findings from the latest PreSCD II analysis show that patients protected against sudden cardiac death by an implantable cardioverter defibrillator (ICD) one month or more after MI showed a non-significantRemarkably," says investigator Professor Heinz Völler from the Klinik am See in Ruedersdorf, Germany, "we observed in the data a survival benefit that increased with the time interval between MI and ICD implantation."

2 Sep 2009

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.

2 Sep 2009

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Primary angioplasty procedures vary in European countries

Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.

2 Sep 2009